PDS Biotech To Event To Discuss Positive, Updated Data From Phase 2 VERSATILE-002 Clinical Trial With Versamune HPV In Combination With KEYTRUDA In Recurrent Or Metastatic Head And Neck Cancer
PDS Biotech To Event To Discuss Positive, Updated Data From Phase 2 VERSATILE-002 Clinical Trial With Versamune HPV In Combination With KEYTRUDA In Recurrent Or Metastatic Head And Neck Cancer
PDS Biotech 将参加活动，讨论针对复发性或转移性头颈癌的 Versamune HPV 与 KEYTRUDA 联合使用的 2 期 VERSATILE-002 临床试验的正面最新数据
Company to Host Key Opinion Leader Event on May 8 at 1:30pm ET to Discuss Updated Results of VERSATILE-002, Unmet Treatment Needs in Advanced Head and Neck Cancer and planned Triple Combination Trial
公司将于美国东部时间5月8日下午 1:30 举办关键意见领袖活动，讨论 VERSATILE-002 的最新结果、晚期头颈癌未满足的治疗需求以及计划中的三联试验